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Background: In an era of scarce and competing priorities for implementation, choosing what to implement is a
key decision point for many behavioural change projects. The values and attitudes of the professionals and
managers involved inevitably impact the priority attached to decision options. Reliably capturing such values is
challenging.
Methods: This paper presents an approach for capturing and incorporating professional values into the
prioritization of healthcare innovations being considered for adoption. Conjoint Analysis (CA) was used in a single
UK Primary Care Trust to measure the priorities of healthcare professionals working with women with postnatal
depression. Rating-based CA data was gathered using a questionnaire and then mapped onto 12 interventions
being considered as a means of improving the management of postnatal depression.
Results: The ‘impact on patient care’ and the ‘quality of supporting evidence’ associated with the potential
innovations were the most influential in shaping priorities. Professionals were least influenced by whether an
innovation was an existing national or local priority, or whether current practice in the Trust was meeting minimum
standards. Ranking the 12 innovations by the preferences of potential adopters revealed ‘guided self help’ was the
top priority for implementation and ‘screening questions for post natal depression’ the least. When other factors
were considered (such as the presence of routine data or planned implementation activity elsewhere in the Trust),
the project team chose to combine the eight related treatments and implement these as a single innovation
referred to as ‘psychological therapies’.
Conclusions: Using Conjoint Analysis to prioritise potential innovation implementation options is a feasible means
of capturing the utility of stakeholders and thus increasing the chances of an innovation being adopted. There are
some practical barriers to overcome such as increasing response rates to conjoint surveys before routine and
unevaluated use of this technique should be considered.
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Innovation implementation (the process of integrating re-
search findings into behaviours at the level of adopters)
happens ‘in context’. Context in many healthcare systems
includes scarce (or at least finite) resources, variability in
adoption of existing innovations, and ways of changing
behaviour that often incur their own costs but are rarely
factored into the final estimate of the cost effectiveness of
innovation adoption [1,2].* Correspondence: katherine.farley@york.ac.uk
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reproduction in any medium, provided the orOne key element of current implementation context is
the growing volume of innovation that health system
decision and policy makers are compelled to consider
for implementation. By way of example, General Practi-
tioners in the UK face up to 30 new pieces of guidance
per month, far more than can feasibly be adopted by a
multidisciplinary team, practice or clinic [3]. Faced with
scarce resources and increasing demand [4], systems must
prioritize and decide which innovations to implement.
Guidance on how prioritization should be undertaken by
potential adopters is scarce.
Policy makers have resorted to economic criteria, such
as cost-effectiveness, to help decide which innovationstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ranking innovations on the basis of economic attributes
such as cost-effectiveness employed by NICE or program
budgeting and marginal analysis [5] misses the role that
other factors play in the choice to adopt or not at service
purchaser or provider levels [4,6,7].
Influential theories of innovation diffusion generally
[7] and healthcare specifically [4,6] suggest multiple gen-
eral determinants of adoption behaviour. Some theorists
[6] identify a large number of possible determinants: the
characteristics of the innovation; system antecedents
(structure of the organisation, absorptive capacity for
new knowledge, and receptive context for change); system
readiness; characteristics of adopters; communication and
influence and a wider ‘outer’ context of politics and struc-
tures. Other models adopt a more parsimonious approach
that focuses on the characteristics of innovations and prior
conditions [7]. The attitudes and values held by potential
adopters exist as variables in almost all theoretical models
of innovation adoption and are a focus within the field of
implementation science [8,9].
Clearly, attitudes are influenced by many factors and
are unlikely to be decisive in themselves in determining
whether an innovation is adopted or behaviour changed.
Indeed, some evidence indicates that, in specific healthcare
contexts, compatibility of guideline attributes with clini-
cians’ values can be negatively related to desired behaviour
change. Foy et al. tested the influence of attributes of clin-
ical recommendations on compliance with recommenda-
tions using a pre- and post-intervention research design
[10]. Foy et al. found that while guideline-norm ‘fit’ and
guideline compliance before and after a behaviour change
intervention (audit and feedback) were positively related,
guideline recommendations seen as incompatible with
clinician norms showed greater change following the
intervention [10]. Foy and colleagues’ pre-post design was
limited by the absence of data points within the interven-
tion period, thus the effects of the intervention on compli-
ance behaviour during the intervention period are
unknown [10]. Further, since Foy et al. used a qualitative
approach to establishing innovation attributes (i.e., using
focus groups and interviews), it is possible that different
experts might have described different attributes.
We sought to use clinicians’ values in a slightly different
way. Rather than evaluating their relationship with the
effect of the behaviour change intervention, we built them
into the selection of an innovation to be implemented.
This study forms the initial phase in developing a targeted
implementation strategy. In the subsequent phase, we
examine six other determinants in order to tailor a multi-
faceted implementation strategy to the barriers associated
with each factor [11]. Our rationale was a simple one:
mindfulness of a ‘fit’ between a potential innovation’s char-
acteristics and potential adopter values and norms wouldlead to focusing on an innovation for implementation that
has (at least) a ‘fighting chance’ of adoption. Omitting to
address the value clinicians assign to the attributes of an
innovation theoretically lowers the chances of the
innovation being adopted [7].
One technique for understanding the value of a prod-
uct’s attributes is Conjoint Analysis. CA is a stated prefer-
ence method with its roots in mathematical psychology
[12,13] and Lancaster’s theory of value [14]. Respondents
are asked to choose between hypothetical products (or
innovations) with different levels of a limited number of
attributes. The findings can then be used to rank compet-
ing innovations whose levels of these attributes have been
scored in advance. CA makes two assumptions: that inno-
vations can be described according to their attributes, and
that the value of an innovation (to an individual) is a prod-
uct of these collective attributes [15]. It has the advantage
of simultaneously estimating the value/utility placed on a
product/service (or innovation) while also identifying the
relative (to other attributes) importance of the attributes
making up the innovation. CA also describes the extent to
which individuals are willing to trade off one attribute to
gain another (for example, cost vs. quality). It has been
applied to many areas: market research [16], private sector
environmental and transport economics, public service
redesign and planning [17]. Specific health applications
include in vitro fertilization [18], orthodontic services
[14,19], and liver transplantation [20]. CA has not been
widely used in implementation research and to the best of
our knowledge has never been used to prioritize possible
targets for implementation efforts.
To demonstrate how this technique can be success-
fully applied to the prioritization of healthcare innova-
tions, we present an application of Conjoint Analysis to
the implementation of innovations for women with post-
natal depression in one UK NHS Primary Care Trust
(PCT). The results are not intended to be generalizable
to other settings; they are presented here to illustrate the
application of CA to a key stage in the implementation
process and the challenges involved.
Methods
Conjoint Analysis
The start point for the project was the selection of 1 (of
a potential 12) recommended innovations for mild to
moderate postnatal depression competing for implemen-
tation resources in the PCT. We followed the five-stage
structure of a typical Conjoint Analysis project [outlined
in Table 1] adapted from Ryan et al. [15]. In addition to
the five stages of a conjoint study, two further stages
were included to apply the technique to the real healthcare
innovations: scoring of potential innovations (treatments)
to be prioritized, and matching of stakeholder preferences
to these innovations.
Table 1 Conjoint Analysis process
Conjoint Analysis requirements Corresponding stage in process
Conjoint Analysis relies on the development of a set of attributes or
criteria that describe a given product.
Stage 1: Identifying plausible and meaningful innovation attributes that
could be used to characterize healthcare innovations (for example,
financial cost).
Levels of each attribute (such as £0, £100, £1,000) for each criterion are
assigned. These need to be meaningful and able to be traded off.
Stage 2: Operationalizing the attributes of innovations and their levels.
Twelve postnatal depression treatments being considered by the Trust
for implementation were described using these attributes.
Hypothetical scenarios with different combinations of attribute levels are
included in the questionnaire.
Stage 3: A fractional factorial design is used to identify the number of
hypothetical scenarios to be included.
Eliciting stakeholder preferences. In choosing or rating, respondents must
trade off some elements of the innovation (for example, cost) for an
increase in another attribute (for example, quality); a process known as
the ‘marginal rate of substitution,’ [12]. Analysis of the choices made yields
estimates of how much respondent stakeholders are prepared to trade off
in their preferred attributes in order to receive their preferred
combination of attributes.
Stage 4: Information about clinician preferences for innovation attributes
is collected using a questionnaire. Respondents rate hypothetical (but
feasible) innovations, products or services described using these criteria.
Analysis reveals the importance of each attribute, and the clinician
preferences for each attribute at each of its component levels.
Alternative methods such as Choice Based Conjoint are available that
quantify individuals’ values in terms of their willingness to pay (WTP) for
an innovation, but rating scales have been shown to perform well in
eliciting preferences for healthcare services [27].
Estimating utilities to determine the importance of each attribute to
stakeholders.
Stage 5: Analysis of data using Sawtooth software provides preference
scores (utilities) for each attribute.
Independent scoring of innovations. Stage 6: ‘Scoring’ of potential postnatal depression treatments using the
attributes and levels identified.
Matching clinician preferences for innovations with the scored
innovations
Stage 7: The 12 innovations were ranked according to the preferences of
the clinicians who would have to implement them.
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The selection of attributes was critical, as omitting
important attributes would weaken the internal validity
of the resulting conjoint design and analysis [21]. We
sought to balance using enough attributes to efficiently
describe a wide range of possible innovations with the
need for the eventual mix to have enough face validity
to be meaningful to both clinicians and policy makers.
Attributes chosen were those that were, first, considered
important by policy makers currently prioritizing re-
sources to support implementation from the Primary
Care Trust; second, described by Rogers’ theoretical
model as ‘perceived attributes’ [7]; and third, that were
theoretically identified barriers to, and facilitators of,
change [4].
Selection of attributes was also guided by criteria
identified by Grimshaw et al.: the local burden of dis-
ease, the availability of ‘effective and efficient healthcare
interventions,’ and ‘local evidence of current suboptimal
performance’ [4]. Because our conjoint exercise was
rooted in a specific local attempt to change behaviour,
we also considered the influence of having routine data
on clinical behaviour available and the policy makers’
need to apply the ascertained preferences to a diverse
range of healthcare innovations in the future. The final
list of attributes is shown in Table 2. One of these attri-
butes was the cost of the innovation, the inclusion of
which makes visible the trade-offs made by cliniciansbetween having more of their preferred attributes and
paying more in resources.
Selection of attributes and the language used to
express them influences the validity of responses [22].
As well as affecting response rates, using attributes that
adequately describe a wide range of types of innovations
improves external validity and generalizability of utilities
to new innovations. To test internal validity, the ques-
tionnaire included five ‘hold out’ questions [23,24].
These hold out tasks were not included in the calculation
of utilities; they were used only to compare modelled and
predicted choices against choices already made [24].
Finally, face validity is tested using qualitative methods,
making it possible to improve attribute selection and
questionnaire design [25]. We gathered informal qualita-
tive feedback from clinicians in similar roles as our study
population to improve our CA questionnaire.
Stage 2: Operationalizing the attributes of innovations and
their levels
Once seven attributes were defined, the component
levels were identified (Table 2). For simplicity and to
maximize response rates, the number of attributes and
levels should be as low as possible [26]. The attributes
were then described in ways that would be meaningful
to stakeholders. While the combinations of attributes
are used to generate hypothetical innovations, it is im-
portant that the attributes themselves have concrete and
Table 2 Attributes and levels
Characteristic Level
Impact on care
Significant improvement
Moderate
Limited
Costs
Low
Moderate
High
Local health needs
Low prevalence
High prevalence
Minimum standards
No, not meeting minimum standards.
Yes, meeting minimum standards.
Strength of supporting evidence
No supporting evidence.
Limited supporting evidence.
Moderate supporting evidence.
Strong supporting evidence.
Priority
National priority.
Local priority.
Both local and national priority.
Existence of local expertise
No, there is no local expertise.
Yes, there is local expertise.
Constant
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presented in a manner as close as possible to the natural
units policymakers encounter. For example, cost was
expressed as pounds (£) per patient, and burden of
disease as prevalence (% of population affected or rate
per 1,000 population members). In order to check the
clarity and wording of the descriptions, identify any
missing attributes and levels, and provide a general
check of the questionnaire, the questionnaire was piloted
with 12 GPs [27].
Stage 3: Identifying which scenarios to present
The SPSS orthoplan (www.spss.com) procedure, based
on the methods for estimating orthogonal main effects
plans of Addelman [28], produced a fractional factorial
design (The SPSS ‘orthoplan’ procedure (www.spss.com)
was used to generate the design) with 16 scenarios.
Details of the decision rules used to reduce the design to
16 scenarios can be found at http://www.springanalytica.
com/UNIZ/PhD/orthoplan.pdf p9. To ensure internal
consistency, five additional scenarios were included that,
rationally, should produce a higher score than others.
Stage 4: Eliciting stakeholder preference using Conjoint
Analysis
Data collection took the form of a rating-based question-
naire. Participants were presented with 16 hypotheticalinnovations, each described by its attributes and varying
levels (for example, innovation A is high cost, has a strong
evidence base, with significant variations in local practice;
innovation B is low cost, has a weaker evidence base, and
less variation in local practice). To indicate the likelihood
of prioritization, participants were asked to rate each of
the series of 16 hypothetical innovations on a seven
point Likert-type scale anchored at ‘Very likely to
prioritize this guideline’ through to ‘Very unlikely to
prioritize this guideline’.
The questionnaire was delivered to 1,200 healthcare
professionals involved in the care of women with post
natal depression (GPs, health visitors, and nurse practi-
tioners). As part of a separate trial comparing postal and
electronic delivery processes, half of the sample was ran-
domly allocated to receive postal questionnaires at their
work address and the other half a personalized email
with a hyperlink to an online version. The questionnaire
was endorsed by the Trust’s Medical Director and
piloted to check that the attributes, language and format
were appropriate. Following best practice guidance on
increasing response rates [29,30], two reminders were
sent to recipients; the first, after two weeks containing a
short text reminding the recipient about the question-
naire. The second was sent three weeks later containing
a second copy of the questionnaire or link to the online
version. The questionnaire was also promoted by tele-
phone by members of the research team in their capacity
as internal Trust auditors and trainers.
Stage 5: Analysis - extracting utilities
Responses were analysed using Sawtooth software’s Con-
joint Value Analysis (CVA module) (www.sawtooth.com).
The analysis is an ordinary least squares regression (OLS)
in which the dependent variable is the priority associated
with an innovation (treated as interval data), and the inde-
pendent variables are the innovation attributes at their
component levels (dummy coded where necessary). The
analysis produces utilities (preference values) for each
attribute and for each level of the attributes. We chose the
simple OLS method of generating utilities from the data,
as OLS is suitable for the ratings-based data we collected,
and also that others wishing to use the technique could do
using easily available statistical software (e.g., Excel, Stata
or SPSS).
Stage 6: ‘Scoring’ of potential innovations for
implementation
The Primary Care Trust provided a list of 12 postnatal de-
pression innovations being considered for implementation.
For each innovation, we used resources such as system-
atic reviews, NICE guidelines, and local data provided
by the Trust to ‘score’ innovations against the attribute
criteria; i.e., according to their cost, quality of their
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ing of the attributes of our ‘real’ postnatal depression
innovations was subjective. The value of using Conjoint
Analysis in this way is the ability to adjust attribute
values to assess the potential impact upon prioritization –
essentially, being able to ask, ‘What if [the innovation had
different attribute values]?’
Stage 7: Matching preferences with scored innovations
In this final stage, the preferences of clinicians were
matched to the 12 postnatal depression innovations. In
order to unite preferences (from Stage 5) and the attri-
butes of the innovations (from Stage 6), the utilities for
each attribute at various levels are summed for each
individual respondent. The option with the highest mean
utility in the sample of clinicians represents the ‘first
choice’ and so the most favoured.
Results
The questionnaire was completed by 11% (N = 139) of
the sample, with an equal number of responses from
postal and email delivery methods.
Stakeholder attribute priorities
The analysis firstly revealed those attributes most
strongly influencing clinicians’ prioritisation decisions.
Table 3 indicates that the attributes with the greatest im-
pact on clinicians’ ratings were the ‘impact on patient care’
and the ‘quality of supporting evidence.’ Stakeholders were
least influenced by whether an innovation was a national
or local priority, or whether current practice was meeting
minimum standards. The internal validity and real-world
applicability of the survey was confirmed as respondents
appear to have responded rationally: ‘Low costs’ were
scored as preferable to ‘high costs’, and ‘significant impact
on care’ scored as preferable to ‘limited impact on care’.
Robustness was further supported with reference to the
hold out cases, which were accurately predicted in the
model with a coefficient of determination (correlationTable 3 Stakeholders’ prioritization of characteristics
Characteristic Ranking from
electronic survey
Ranking from
paper survey
Impact on care 1 2
Strength of supporting
evidence
2 1
Local health needs of
patients/clients
3 3
Costs associated with new
ways of working
4 4
Local expertise 5 5
Meeting minimum
standards
6 6
National or local priority 7 7coefficient squared) of 93% (Pearson’s r = .96, p < 0.001).
This figure indicates the proportion of the expected pref-
erence explained by the actual preference [30].
Linking priorities with innovation attributes
Each innovation was independently assessed using the
seven attributes. Table 4 shows the attributes assigned to
each innovation. The reader will note that three of the
attributes are (necessarily) ‘fixed’ in our illustrative example:
‘local health needs,’ ‘local expertise,’ ‘minimum standards.’
The technique’s application here is to a problem in which
policy makers faced competing priorities for innovation
investment/adoption within a single clinical domain: post
natal depression. Hence ‘need,’ ‘local expertise’ [in managing
PND], and ‘standards of care’ [associated with PND] did
not vary. In other applications, the priorities for innovation
adoption will cross clinical domains or problem areas and
so attributes will vary.
After ranking the 12 innovations according to the pref-
erences for their attributes (Table 5), ‘guided self help’ was
the top priority for implementation and ‘screening ques-
tions for post natal depression’ the least. The ‘diagnostic
tool’ was the innovation that was ranked first solely on
preferences. However, the team and PCT end user of the
analysis had also to consider factors important in the NHS
health economy served by the project. These included ap-
plication to adequate service-user numbers, the number of
clinicians associated with the interventions, other related
activity within the Trust, data availability, the recording
process, and commissioning patterns locally. We did not
include these factors in the design for two reasons. Firstly,
in conjoint designs, the number of attributes affects the
number of scenarios included in the survey as well as the
required sample size. Including more than seven attributes
would have required a far larger number of scenarios
given the sample size. Secondly, these were pragmatic fac-
tors that were difficult to categorize in levels suitable for
conjoint designs. Once these considerations were added to
the information on preferences alone, the study team
chose to implement a combination of eight psychological
therapy interventions.
Utilities of attributes
Table 6 provides the utilities for each attribute at each of
their levels. Stage 5 produced a ranked list of the potential
innovations. Thus, the final rank reflects the value of the
innovation for the clinician sample given the attributes of
the innovations.
Consider Table 6, which contains two example hypo-
thetical innovations that we shall call, ‘Innovation A’ and
‘Innovation B.’ We can see that hypothetical ‘Innovation
A’ has a significant impact on care, with strong supporting
evidence, is able to be delivered at moderate cost, applies
to patients with a high prevalence condition, is a national
Table 4 Independent assessment of postnatal depression innovations (allocation of criteria)
Innovation Impact on
care
Strength of
evidence
Local health
needs
Costs Local
expertise
Min.
standards
Priority
NICE diagnostic questions Limited No evidence High Low Yes No Local
Guided self help Moderate Moderate High Low Yes No National and
local
Computerised CBT Limited Moderate High Low Yes No National and
local
Exercise Limited Limited High Moderate Yes No Local
Health visitor listening visits Moderate Moderate High Moderate Yes No National and
local
Practice counsellor referral Moderate Moderate High High Yes No National and
local
Brief CBT Limited Limited High Moderate Yes No National and
local
Full CBT Moderate Limited High High Yes No National and
local
Anti- depressants Limited Limited High Low Yes No Local
Anti-depressants and psychological
therapies together
Limited Moderate High Low Yes No Local
EPDS diagnostic tool Moderate Limited High Low Yes No Local
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meeting minimum standards. Thus, innovation A has a
total utility of:
Constant + utility for attribute A + utility for attribute
B + utility for attribute k Or 0.05 + −.023 + −0.09 + 0.21 +
0.32 + 0.40 +0.25 + 0.02 = 0.94
In contrast, ‘Innovation B’ has a significant impact on
care, has only moderate supporting evidence, but is de-
liverable at low cost, to a high prevalence patient group,
local expertise is present, is a recognized local priority,
and minimum standards are not being met. InnovationTable 5 Ranking of postnatal depression innovations
Innovation Rank from
postal
Rank from
electronic
Guided self help 1 1
HV listening visit 2 2
EPDS 3 4
Practice counsellor 4 3
Full CBT 5 6
Computerised CBT 6 5
Anti-depressants and psychological
therapy
7 7
Anti-depressants 8 9
Brief CBT 9 8
Exercise 10 10
NICE screening questions 11 11B would have a total utility of −0.15. Thus, innovation A
is preferred over innovation B. Examining the total utilities
for the actual postnatal depression innovations enabled us
to produce a list of the 12 innovations (Table 5) ranked
by the predicted utility (value) that the respondents
would get from the innovation. Of these 12 innovations,
we selected 8 related innovations which we combined
to make one single innovation: ‘psychological therapies,’
the aim being to increase the adoption of any one of
these therapies.
Discussion
Using the results of a local survey conducted in a Primary
Care Trust, this paper describes one solution to the
challenge of incorporating clinician preferences into the
prioritization of innovations in healthcare systems in
which resources are finite and limited. In doing so, this
study demonstrates the feasibility of the application of
Conjoint Analysis to implementation. The analysis pro-
vided three things:
1. The importance of the attributes of innovations
generally;
2. Their importance at various levels;
3. And a ranked picture of innovations according to
the preferences of the people involved in having to
implement them.
There are other widely used methods for prioritizing
innovations for adoption or investment. Criteria such as
multi-criteria decision analysis [31], budget impact
Table 6 Utilities of innovation characteristics
Characteristic Level Utility estimate Std. error Innovation A Innovation B
Impact on care Significant improvement -0.228 0.111 √ √
Moderate 0.078 0.130
Limited 0.150 0.130
Costs Low 0.252 0.111 √
Moderate -0.090 0.130 √
High -0.162 0.130
Local health needs Low prevalence -0.207 0.083
High prevalence 0.207 0.083 √ √
Minimum standards No, not meeting minimum standards. -0.324 0.083 √
Yes, meeting minimum standards. 0.324 0.083 √
Strength of supporting evidence No supporting evidence. -0.243 0.144
Limited supporting evidence. -0.135 0.144
Moderate supporting evidence. -0.027 0.144 √
Strong supporting evidence. 0.405s 0.144 √
Priority National priority -0.108 0.111 √
Local priority -0.144 0.130 √
Both local and national priority 0.252 0.130
Existence of local expertise No, there is no local expertise. 0.018 0.083 √
Yes, there is local expertise. -0.018 0.083 √
Constant 0.048 0.096
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useful. However, the conjoint analytic approach enabled
us to consider the innovation options most likely to ‘fit’
local preferences before we developed an implementa-
tion strategy that went on to measure and target other
determinants of innovation adoption. Improving the ‘fit’
with local values as well as mapping and targeting the
multitude of other determinants, should – in theory –
increase the efficiency of the eventual implementation
strategy [6]. A more efficient implementation strategy
will, all things being equal, reduce the costs of behaviour
change approaches and thus increase ‘policy cost effect-
iveness’ – i.e., an estimate of costs vs. impact that takes
into account the costs of changing behaviour as well as
the cost effectiveness of the innovation itself [1].
By applying Conjoint Analysis to healthcare innovation
preferences for implementation, we were able to provide
a visible rationale for the decision of which innovation
to invest scarce time, money and human resources on.
To the best of our knowledge, this is the first time CA
has been used in implementation science in this way.
Previous applications of CA to service improvement, de-
sign or planning have primarily been designed to inform
single services (for example, [18,19]). While applying CA
to single service design or improvement may be valu-
able, it may not be efficient. Because CA utilities relate
to the attributes of products or services, CA results canalso be used in the future for ‘different-but-similar’ prod-
ucts. Enabling organizations to reuse preferences that
can be applied to a range of topics and innovations, CA
could be a more efficient means of gathering stakeholder
data than repeatedly surveying people.
There remain some challenges in applying CA. Per-
haps the most significant is identifying effective sampling
strategies and achieving high response rates. Despite
adhering to evidence-based sampling strategies [34], our
exercise resulted in only an 11% response rate. Conjoint
Analysis questionnaires in healthcare can be complex, a
complexity that is exacerbated because decomposing
and describing healthcare innovations on the basis of
their compound attributes is difficult. Making descriptions
informative, nuanced and yet meaningful and accessible
(to non-technical audiences) is difficult. Healthcare tech-
nologies and the factors involved in decision-making in
this sector may be more numerous than for products in
which Conjoint Analysis has been traditionally used.
Higher response rates have been achieved in other
healthcare contexts, suggesting that this challenge can be
overcome [21,35].
A second difficulty is that the stability of stakeholder
preferences over time is less well known. Although some
studies in non-healthcare contexts suggest that prefer-
ences are relatively stable [36,37], there is scope for fu-
ture research into the effect of time on preferences.
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applied to future innovation implementation choices.
More work is required to establish the stability of prefer-
ences in this context.
Balancing conciseness of language in the questionnaire
and meaningfulness to clinicians was challenging. A fur-
ther challenge was identifying attributes and levels that
could be applied to a diverse range of innovations; for ex-
ample, diagnostic techniques and treatment modalities.
While ratings-based conjoint was preferred in our
context [34], rating questionnaires can be difficult to
complete. More technically, individual-level utilities are
not available in ratings approaches. A variant of CA,
Discrete Choice Experimentation (DCE), offers an alter-
native built around random utility theory (RUT). DCE is
widely used in health economics [25]. In contrast to
rating-based Conjoint Analysis, respondents are faced
with direct choices between options (‘Of these two
options which would you choose?’), an approach that
mirrors real decision making.
Finally, the CA approach outlined in this paper applied
only to the adoption of innovations into a healthcare
system. The approach tells us nothing about the choices
people make to stop using or dis-adopt an intervention.
There is considerable scope for adapting the approach to
examining the relationship between value and norm
compatibility and behaviour that is not desired by those
seeking to foster sustainable adoption.Conclusions
Increasingly, healthcare systems are faced with the prob-
lem of which innovations to implement. Conventional
methods of prioritization are often intuitive, opaque, and
based on socio-political factors such as which stake-
holder group voice carries the most weight. There are
other determinants of course, but the probability of in-
novations being adopted is influenced – if only in part –
by the values and preferences of professionals (potential
adopters) in healthcare systems and the characteristics
of innovations. However, preferences can be difficult to
gather and analyze systematically, rigorously, reliably
and efficiently. Conjoint Analysis, with its central premise
that an innovation’s value is the sum of its components,
holds considerable promise. This paper has shown that
despite the practical hurdles to be overcome, the proof of
principle exists: preferences can be mapped, matched to
innovation characteristics, and used to shape the design
and implementation of interventions to change behaviour
and encourage adoption.Ethical approval
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